According to a study conducted at the Dana-Farber Cancer Institute, a key design element present in a phase III clinical trial has led to worldwide approval of sunitinib for treating gastrointestinal stromal tumors (GIST).
Sunitinib, a small molecule inhibitor of KIT, was approved by the FDA in 2006 for treating patients with imatinib resistant/intolerant GIST. As indicated by this study, clinical trials are essential in understanding the drug development process: "these goals really are possible to achieve by designing studies around the best science and choosing diseases that are deeply understood at a molecular level, such as GIST."
To read more about this trial, click here.
No comments:
Post a Comment